HEALTH

PYC Therapeutics' stock rose 7.06% amid ongoing advancements in RNA-based treatments for rare genetic diseases, supported by a strong financial position and promising clinical trial results.

4DMedical's stock has surged 1,250% over the past year, driven by strategic acquisitions, new contracts, and expanding market presence, despite ongoing volatility and valuation concerns.

The U.S. Department of Veterans Affairs is conducting a clinical trial to test if semaglutide, a diabetes medication, can help veterans with alcohol addiction by affecting the brain's reward system.

Abbott Laboratories' shares rose 2.37% after reporting strong Q2 results and raising its 2026 earnings guidance, driven by growth in diagnostics, devices, and strategic acquisitions.

Huron Consulting Group's stock surged 32.11% after reporting Q2 earnings that exceeded expectations and raising its full-year guidance, driven by growth in AI-related services and recent acquisitions.

AbbVie shares reached a 52-week high as investors anticipate the company's second-quarter earnings report, focusing on its immunology portfolio and recent strategic acquisitions.

Johnson & Johnson's shares soared to a record high after agreeing to a $5.5 billion settlement to resolve 76,000 U.S. lawsuits alleging its talc products caused ovarian cancer, removing a major legal overhang.

Kiniksa Pharmaceuticals' shares rose over 21% following strong Q2 results, surpassing expectations and raising its full-year sales outlook for ARCALYST, the only FDA-approved therapy for recurrent pericarditis.

Microsoft introduces MAI-Cyber-1-Flash, an AI model designed to identify cybersecurity vulnerabilities, outperforming rivals at lower costs. Integrated into Project Perception, it marks a significant shift in Microsoft's security strategy.

Thermo Fisher Scientific's shares surged after reporting strong Q2 results, surpassing expectations and raising full-year guidance, indicating a recovery in the life sciences sector.

Taco Bell introduces $1 menu deals to attract customers back after a cyclospora outbreak linked to its lettuce. The company swiftly removed the affected produce and continues to investigate the source.

NovoCure's shares jumped 25% following record quarterly revenue and an improved financial outlook, marking a recovery from earlier setbacks, including a failed clinical trial and insider share sales.

The FDA corrected a false positive test for Cyclospora in Taylor Farms de Mexico's lettuce, but the recall remains as the investigation into the outbreak affecting over 1,600 people continues.

A cyclosporiasis outbreak linked to Taco Bell's lettuce has sickened thousands across 34 states. The CDC advises against consuming the lettuce, while Taco Bell and Taylor Farms take corrective actions.

Trevi Therapeutics' stock rose 13.10% following positive data presentation at a European conference, highlighting Haduvio's potential in treating chronic cough, boosting investor confidence and analyst ratings.

4DMedical shares dropped 15.57% this week, continuing a downward trend as investors reassess the company's valuation. Despite recent commercial successes, market sentiment remains cautious amid broader volatility.

A potential cyclospora outbreak linked to Taylor Farms' lettuce has affected Taco Bell locations, with nearly 7,000 cases reported nationwide. Investigations are ongoing to confirm the source.

Johnson & Johnson's stock fell despite exceeding Q2 earnings expectations, as investor optimism had already been priced in. The company raised its full-year guidance, aiming for a historic revenue milestone.

Lupin Pharmaceuticals recalls over 2.5 million bottles of Prednisolone Acetate eye drops due to potential contamination, urging patients to verify their prescriptions against FDA's recall list.

Eli Lilly's shares dipped slightly after reaching a record high, buoyed by positive analyst commentary and strong financial performance. Analysts continue to raise price targets amid regulatory and competitive challenges.

Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for $10 billion, enhancing its endocrinology portfolio with key assets like Palsonify and atumelnant, pending regulatory approvals.

Agios Pharmaceuticals' stock surged after the FDA granted priority review to its drug mitapivat for sickle cell disease, potentially accelerating its market entry and expanding its commercial reach.

SL Science Holding Limited's Nasdaq debut has seen significant share price volatility, drawing investor interest in its innovative cell and gene therapies targeting solid tumors, despite inherent biotech risks.

SL Science's shares rose 34% post-Nasdaq listing via SPAC merger, highlighting investor interest in its innovative cell therapy platforms targeting solid tumors and regenerative medicine applications.

Moderna's stock surged over 10% as investors responded positively to its expanding mRNA pipeline, despite ongoing challenges in the post-COVID landscape and mixed analyst opinions on long-term growth.

Merck & Co. shares fell over 2% due to market shifts and sector volatility. Despite challenges, Merck's oncology and vaccine sales provide stability, while strategic acquisitions bolster its pipeline.

Abivax shares surged after new trial data eased cancer concerns linked to its ulcerative colitis drug, obefazimod. The data showed reassuring safety and efficacy results, boosting investor confidence.

The ASX 200 closed nearly unchanged, buoyed by a biotech surge and easing geopolitical tensions, while investors await Chinese manufacturing data and Reserve Bank policy updates.

Neuren Pharmaceuticals' shares rose 36% after its Rett syndrome drug received a positive EU recommendation, marking a significant milestone for the rare disease treatment.